Bestowed annually, the Bloom Burton Award honours an individual scientist, inventor, executive, entrepreneur, industry leader, or policy maker who made the greatest contribution to Canada’s innovative healthcare industry in the previous year. Nominees will be accepted from any of the biotechnology, pharmaceutical, medical device, diagnostic/imaging, research instrumentation, consumer health, services or healthcare IT sectors, and equal consideration will be given to contributions across any stage of development – from discovery to commercial end markets.
The Bloom Burton Award winner will be chosen from an esteemed panel of judges, all of whom are respected international leaders in healthcare investment, entrepreneurship and journalism.
Our esteemed panel of judges are respected international leaders in healthcare investment, entrepreneurship and journalism:
Karen Bernstein, Co-Founder and Chairman, BioCentury Inc.
Cecilia Gonzalo, Managing Director, Vatera Healthcare Partners
Carl Gordon, Partner and Co-Head of Global Private Equity, OrbiMed Advisors
Dennis Purcell, Founder and Senior Advisory, Aisling Capital
Melinda Richter, Global Head of Johnson & Johnson Innovation, JLABS
Avik Roy, Opinion Editor, Forbes; President, The Foundation for Research and Equal Opportunity
Mayukh Sukhatme, Chief Business Officer, Roivant Sciences
Our three finalists, Clarissa Desjardins, Richard Glickman and Ali Tehrani will be celebrated for their incredible contributions to the Canadian healthcare sector. Each of the finalists will receive a $25,000 cash prize, and a single winner will have the honour of being the 2018 Bloom Burton Award recipient.
Dr. Clarissa Desjardins founded Clementia in 2011 and has served as the company’s chief executive officer since then. Prior to Clementia, she was CEO at the Centre d’excellence en médecine personnalisée (CEPMED), a Montreal-based federally and privately funded non-profit enterprise created to promote personalized medicine.
Dr. Desjardins is an award-winning entrepreneur with more than 18 years of biotechnology experience. She has founded three successful biotech companies, leading all aspects of company creation including conception and financing. She founded Advanced Bioconcept, a research reagent and diagnostics company sold to NEN Life Sciences (Perkin Elmer) in 1998. Dr. Desjardins also co-founded Caprion Pharmaceuticals, a biotechnology company focused on proteomic biomarker discovery and drug development, where she was executive vice-president of corporate development.
She received the BRIO award for outstanding contributions to the biotechnology industry from the Quebec Biotechnology Association and was named one of the top young Canadians likely to influence the future by the Globe and Mail. Dr. Desjardins has been a board member of numerous companies, including the scientific advisory council of the Canadian Academy of Sciences.
Dr. Desjardins earned a doctorate in neurology and neurosurgery from McGill University’s Faculty of Medicine and was a Medical Research Council postdoctoral fellow at the Douglas Hospital Research Centre.
Dr. Richard Glickman presently serves as the CEO and Chairman of the Board of Aurinia Pharmaceuticals. In addition to being a Founder of the company, he previously served as the Interim Executive Chairman of the Company for the period September 20, 2013 to February 28, 2014 and as Acting Interim CEO for the period October 22, 2013 to November 5, 2013.
He was a co-founder, Chairman and CEO of Aspreva Pharmaceuticals (“Aspreva”), playing an integral role in the development and establishment of CellCept®, or MMF, as the current standard of care for lupus nephritis. Aspreva Pharmaceuticals was acquired by Swiss pharmaceutical company Galenica for nearly $1B in 2008. He currently serves as founding Chairman of Essa Pharmaceuticals Inc., Chairman of the Board of Engene Corporation and a Director of Cardiome Pharma. He is also a Partner at Lumira Capital, one of Canada’s most successful healthcare focused venture capital firms. Dr. Glickman has served on numerous biotechnology and community boards, including member of the federal government’s National Biotechnology Advisory Committee, Director of the Canadian Genetic Disease Network, Chairman of Life Sciences B.C. and a member of the British Columbia Innovation Council. Dr. Glickman is the recipient of numerous awards including the Ernst and Young Entrepreneur of the Year, a recipient of both BC and Canada’s Top 40 under 40 award, the BC Lifesciences Leadership Award and the Corporate Leadership Award from the Lupus Foundation of America (LFA).
Dr. Ali Tehrani is one of the co-founders of Zymeworks and currently serves the President and Chief Executive Officer. Dr. Tehrani has served as a member of our Board of Directors since the Company’s inception in September 2003. He has been an integral part of Zymeworks’ numerous corporate achievements including raising seed and angel financing and overseeing the technical operations and patent filings.
Dr. Tehrani holds both Bachelors and Masters of Science degrees in Biochemistry from the University of Massachusetts, and has a Doctoral degree in Microbiology and Immunology from the University of British Columbia. While completing his Ph.D. degree he co-founded the Student Biotechnology Network, for which he received the UBC Faculty of Science Achievement Award for Outstanding Leadership in 2002. Dr. Tehrani has served as a board director for the Student Biotechnology Network and LifeSciences British Columbia, on the MITACS Industrial Advisory Board, and on BIOTECanada’s Industrial and Environmental Committee. Currently, he is a member of the board of directors of Creatus Biosciences Inc. and CQDM and a Council Member on British Columbia’s Premier’s Technology Council.
Tel: (416) 640-7580